Mitral regurgitation (MR) severity is an important determinant of symptom status and
prognosis in heart failure with reduced ejection fraction (HFrEF). Functional MR is frequently …

Functional mitral regurgitation (FMR) is common in heart failure with reduced ejection
fraction (HFrEF) and is associated with an adverse prognosis (1). Clinical trials of drug …

Abstract Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …

Secondary mitral regurgitation (MR) is the result of intrinsic dysfunction of the failing left
ventricle (LV) in the absence of organic mitral valve dysfunction. The mitral valve apparatus …

Background Major classes of medical therapy for heart failure with reduced ejection fraction
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …

Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …

Background In patients with heart failure with reduced ejection fraction (HFrEF), treatment
with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Background: While disease-modifying therapies exist for heart failure (HF) with reduced left
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …

Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …